

S3 Table. Cox proportional hazard model for progression-free survival

| Variable | Reference | Univariate analysis | | | | |
|---|----------------|---------------------|----------------|-------------------|---------------|----------------|
| | | Parameter estimate | Standard error | Hazard ratio (HR) | 95% CI for HR | p-value |
| Age | | | | | | |
| ≥75 yr | <75 yr | -0.4494 | 0.2295 | 0.64 | 0.41-1.00 | 0.0502 |
| Smoking history | | | | | | |
| Former or Current | Never | -0.2248 | 0.1371 | 0.80 | 0.61-1.04 | 0.1010 |
| Histology | | | | | | |
| Squamous cell carcinoma | Adenocarcinoma | -0.2685 | 0.1465 | 0.76 | 0.57-1.02 | 0.0668 |
| Brain metastasis | | | | | | |
| Yes | No | 0.1093 | 0.1647 | 1.12 | 0.81-1.54 | 0.5070 |
| Liver metastasis | | | | | | |
| Yes | No | 0.3027 | 0.2017 | 1.35 | 0.91-2.01 | 0.1334 |
| ECOG PS | | | | | | |
| 2 | 0-1 | 0.2760 | 0.1962 | 1.32 | 0.90-1.94 | 0.1595 |
| Previous treatment line (1, ≥ 2) | | | | | | |
| ≥2 | 1 | 0.2238 | 0.1478 | 1.25 | 0.94-1.67 | 0.1299 |
| Immune-related AE | | | | | | |
| Yes | No | -0.7697 | 0.1494 | 0.46 | 0.35-0.62 | < 0.001 |
| EGFR | | | | | | |
| Positive | Negative | 0.0666 | 0.2050 | 1.07 | 0.72-1.60 | 0.7453 |

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; AE, adverse effect; EGFR, epidermal growth factor receptor.